A review of 11 studies suggests endometriosis may take a cumulative toll on work, but long-term data are scarce.
With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results